Lyell Immunopharma (NASDAQ: LYEL) insider transactions
In the twelve months to 10 November 2026, executives and directors of Lyell Immunopharma reported 25 open-market sales of 30,391 shares ($593,981) and 4 open-market purchases of 5,618,704 shares ($75.0m), by 11 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 4 November 2026 | ARCH Venture Fund XIII, L.P. | — | Open-market purchase | +2,321,262 | $10.77 | 3,747,790 | Form 4 |
| 4 November 2026 | ARCH Venture Partners IX, LLC | — | Open-market purchase | +2,321,262 | $10.77 | 3,747,790 | Form 4 |
| 12 October 2026 | Aguirre Jarrad Mattieu | Chief Medical Officer | Open-market sale | −422 | $8.63 | 19,857 | Form 4 |
| 10 September 2026 | Shook David | Chief Medical Officer | Open-market sale | −500 | $12.70 | 20,423 | Form 4 |
| 21 August 2026 | Seely Lynn | President and CEO | Open-market sale | −9,589 | $15.54 | 63,899 | Form 4 |
| 21 August 2026 | Hill Stephen J. | Chief Operating Officer | Open-market sale | −989 | $15.54 | 16,816 | Form 4 |
| 21 August 2026 | Lee Gary K. | Chief Scientific Officer | Open-market sale | −1,457 | $15.54 | 16,220 | Form 4 |
| 10 August 2026 | Seely Lynn | President and CEO | Open-market sale | −390 | $14.34 | 73,488 | Form 4 |
| 10 August 2026 | Hill Stephen J. | Chief Operating Officer | Open-market sale | −89 | $14.34 | 17,805 | Form 4 |
| 10 August 2026 | Lee Gary K. | Chief Scientific Officer | Open-market sale | −131 | $14.34 | 17,677 | Form 4 |
| 10 August 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | Open-market sale | −621 | $14.34 | 14,799 | Form 4 |
| 27 July 2026 | Innovative Cellular Therapeutics Holdings Ltd | — | Other | −38,500 | — | 2,818,980 | Form 4 |
| 27 July 2026 | Innovative Cellular Therapeutics Holdings Ltd | — | Other | −44,000 | — | 2,774,980 | Form 4 |
| 17 July 2026 | Innovative Cellular Therapeutics Holdings Ltd | — | Open-market sale | −10 | $13.70 | 2,857,480 | Form 4 |
| 16 July 2026 | Innovative Cellular Therapeutics Holdings Ltd | — | Open-market sale | −10 | $13.73 | 2,857,490 | Form 4 |
| 29 June 2026 | Innovative Cellular Therapeutics Holdings Ltd | — | Other | −76,000 | — | 2,857,500 | Form 4 |
| 15 June 2026 | Innovative Cellular Therapeutics Holdings Ltd | — | Other | −66,500 | — | 2,933,500 | Form 4 |
| 10 June 2026 | Shook David | Chief Medical Officer | Open-market sale | −1,977 | $12.64 | 20,923 | Form 4 |
| 11 May 2026 | Seely Lynn | President and CEO | Open-market sale | −388 | $18.91 | 73,878 | Form 4 |
| 11 May 2026 | Hill Stephen J. | Chief Operating Officer | Open-market sale | −89 | $18.92 | 17,894 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Lyell Immunopharma page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.